• 1
    Connelly LB, Woolf A, Brooks P. Cost-effectiveness of interventions for musculoskeletal conditions. Disease control in developing countries. Washington, DC: World Bank; 2006.
  • 2
    Connelly LB, Supangan R. The economic costs of road traffic crashes: Australia, states and territories. Accid Anal Prev. 2006 Nov; 38(6):108793.
  • 3
    Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res. 2007 Mar; 22(3):46575.
  • 4
    Marks R. Hip fracture epidemiological trends, outcomes, and risk factors, 1970-2009. Int J Gen Med. 2010; 3:117.
  • 5
    Janssen I, Shepard DS, Katzmarzyk PT, Roubenoff R. The healthcare costs of sarcopenia in the United States. J Am Geriatr Soc. 2004 Jan; 52(1):805.
  • 6
    Fielding RA, Vellas B, Evans WJ, Bhasin S, Morley JE, Newman AB, Abellan van Kan G, Andrieu S, Bauer J, Breuille D, Cederholm T, Chandler J, De Meynard C, Donini L, Harris T, Kannt A, Keime Guibert F, Onder G, Papanicolaou D, Rolland Y, Rooks D, Sieber C, Souhami E, Verlaan S, Zamboni M. Sarcopenia: an undiagnosed condition in older adults. Current consensus definition: prevalence, etiology, and consequences. International working group on sarcopenia. J Am Med Dir Assoc. 2011 May; 12(4):24956.
  • 7
    Frisoli A Jr, Chaves PH, Ingham SJ, Fried LP. Severe osteopenia and osteoporosis, sarcopenia, and frailty status in community-dwelling older women: results from the Women's Health and Aging Study (WHAS) II. Bone. 2011 Apr 1; 48(4):9527.
  • 8
    Di Monaco M, Vallero F, Di Monaco R, Tappero R. Prevalence of sarcopenia and its association with osteoporosis in 313 older women following a hip fracture. Arch Gerontol Geriatr. 2011 Jan–Feb; 52(1):714.
  • 9
    Pollack NK, Hamrick MW. Muscle and bone: meeting report from the 32nd annual meeting of the American Society for Bone and Mineral Research. BoneKEy. 2010; 7(12):4736.
  • 10
    Hamrick M. JMNI special issue: basic science and mechanisms of muscle-bone interactions. J Musculoskelet Neuronal Interact. 2010 Mar; 10(1):12.
  • 11
    Sharir A, Stern T, Rot C, Shahar R, Zelzer E. Muscle force regulates bone shaping for optimal load-bearing capacity during embryogenesis. Development. 2011 Aug; 138(15):324759.
  • 12
    Frost HM. Muscle, bone, and the Utah paradigm: a 1999 overview. Med Sci Sports Exerc. 2000; 32(5):9117.
  • 13
    Bren-Mattison Y, Hausburg M, Olwin BB. Growth of limb muscle is dependent on skeletal-derived Indian hedgehog. Dev Biol. 2011 Aug 15; 356(2):48695.
  • 14
    Tsampalieros A, Gupta P, Denburg MR, Shults J, Zemel BS, Mostoufi-Moab S, Wetzsteon RJ, Herskovitz RM, Whitehead KM, Leonard MB. Glucocorticoid effects on changes in bone mineral density and cortical structure in childhood nephrotic syndrome. J Bone Miner Res. 2013 Mar; 28(3):4808.
  • 15
    Amin S, Riggs BL, Atkinson EJ, Oberg AL, Melton LJ 3rd, Khosla S. A potentially deleterious role of IGFBP-2 on bone density in aging men and women. J Bone Miner Res. 2004 Jul; 19(7):107583.
  • 16
    Lebrasseur NK, Achenbach SJ, Melton LJ 3rd, Amin S, Khosla S. Skeletal muscle mass is associated with bone geometry and microstructure and serum insulin-like growth factor binding protein-2 levels in adult women and men. J Bone Miner Res. 2012 Oct; 27(10):215969.
  • 17
    Vogt PM, Boorboor P, Vaske B, Topsakal E, Schneider M, Muehlberger T. Significant angiogenic potential is present in the microenvironment of muscle flaps in humans. J Reconstr Microsurg. 2005 Nov; 21(8):51723.
  • 18
    Riggs BL, Khosla S, Melton LJ 3rd. Sex steroids and the construction and conservation of the adult skeleton. Endocr Rev. 2002 Jun; 23(3):279302.
  • 19
    Haran PH, Rivas DA, Fielding RA. Role and potential mechanisms of anabolic resistance in sarcopenia. J Cachexia Sarcopenia Muscle. 2012 Sep; 3(3):15762.
  • 20
    Davidson LE, Rosenberg ML, Mercy JA, Franklin J, Simmons JT. An epidemiologic study of risk factors in two teenage suicide clusters. JAMA. 1989 Nov 17; 262(19):268792.
  • 21
    Roubenoff R. Origins and clinical relevance of sarcopenia. Can J Appl Physiol. 2001 Feb; 26(1):7889.
  • 22
    Morley JE, Abbatecola AM, Argiles JM, Baracos V, Bauer J, Bhasin S, Cederholm T, Coats AJ, Cummings SR, Evans WJ, Fearon K, Ferrucci L, Fielding RA, Guralnik JM, Harris TB, Inui A, Kalantar-Zadeh K, Kirwan BA, Mantovani G, Muscaritoli M, Newman AB, Rossi-Fanelli F, Rosano GM, Roubenoff R, Schambelan M, Sokol GH, Storer TW, Vellas B, von Haehling S, Yeh SS, Anker SD. Sarcopenia with limited mobility: an international consensus. J Am Med Dir Assoc. 2011 Jul; 12(6):4039.
  • 23
    Berger MJ, Doherty TJ. Sarcopenia: prevalence, mechanisms, and functional consequences. Interdiscip Top Gerontol. 2010; 37:94114.
  • 24
    Thomas DR. Sarcopenia. Clin Geriatr Med. 2010 May; 26(2):33146.
  • 25
    Muscaritoli M, Anker SD, Argiles J, Aversa Z, Bauer JM, Biolo G, Boirie Y, Bosaeus I, Cederholm T, Costelli P, Fearon KC, Laviano A, Maggio M, Rossi Fanelli F, Schneider SM, Schols A, Sieber CC. Consensus definition of sarcopenia, cachexia and pre-cachexia: joint document elaborated by Special Interest Groups (SIG) “cachexia-anorexia in chronic wasting diseases” and “nutrition in geriatrics.”. Clin Nutr. 2010 Apr; 29(2):1549.
  • 26
    Lang TF, Sigurdsson S, Karlsdottir G, Oskarsdottir D, Sigmarsdottir A, Chengshi J, Kornak J, Harris TB, Sigurdsson G, Jonsson BY, Siggeirsdottir K, Eiriksdottir G, Gudnason V, Keyak JH. Age-related loss of proximal femoral strength in elderly men and women: the Age Gene/Environment Susceptibility Study—Reykjavik. Bone. 2012 Mar; 50(3):7438.
  • 27
    Cham R, Perera S, Studenski SA, Bohnen NI. Age-related striatal dopaminergic denervation and severity of a slip perturbation. J Gerontol A Biol Sci Med Sci. 2011 Sep; 66(9):9805.
  • 28
    Clark BC, Manini TM. Sarcopenia =/= dynapenia. J Gerontol A Biol Sci Med Sci. 2008 Aug; 63(8):82934.
  • 29
    Wong IP, Zengin A, Herzog H, Baldock PA. Central regulation of bone mass. Semin Cell Dev Biol. 2008 Oct; 19(5):4528.
  • 30
    Karasik D, Kiel DP. Evidence for pleiotropic factors in genetics of the musculoskeletal system. Bone. 2010 May; 46(5):122637.
  • 31
    Perrini S, Laviola L, Carreira MC, Cignarelli A, Natalicchio A, Giorgino F. The GH/IGF1 axis and signaling pathways in the muscle and bone: mechanisms underlying age-related skeletal muscle wasting and osteoporosis. J Endocrinol. 2010 Jun; 205(3):20110.
  • 32
    Tsuchida K. Targeting myostatin for therapies against muscle-wasting disorders. Curr Opin Drug Discov Devel. 2008 Jul; 11(4):48794.
  • 33
    Elkasrawy MN, Hamrick MW. Myostatin (GDF-8) as a key factor linking muscle mass and bone structure. J Musculoskelet Neuronal Interact. 2010 Mar; 10(1):5663.
  • 34
    Hamrick MW, Arounleut P, Kellum E, Cain M, Immel D, Liang LF. Recombinant myostatin (GDF-8) propeptide enhances the repair and regeneration of both muscle and bone in a model of deep penetrant musculoskeletal injury. J Trauma. 2010 Sep; 69(3):57983.
  • 35
    Trendelenburg AU, Meyer A, Jacobi C, Feige JN, Glass DJ. TAK-1/p38/nNFkappaB signaling inhibits myoblast differentiation by increasing levels of activin A. Skelet Muscle. 2012; 2(1):3.
  • 36
    Trendelenburg AU, Meyer A, Rohner D, Boyle J, Hatakeyama S, Glass DJ. Myostatin reduces Akt/TORC1/p70S6K signaling, inhibiting myoblast differentiation and myotube size. Am J Physiol Cell Physiol. 2009 Jun; 296(6):C125870.
  • 37
    Redlich K, Smolen JS. Inflammatory bone loss: pathogenesis and therapeutic intervention. Nat Rev Drug Discov. 2012 Mar; 11(3):23450.
  • 38
    Mavalli MD, DiGirolamo DJ, Fan Y, Riddle RC, Campbell KS, van Groen T, Frank SJ, Sperling MA, Esser KA, Bamman MM, Clemens TL. Distinct growth hormone receptor signaling modes regulate skeletal muscle development and insulin sensitivity in mice. J Clin Invest. 2010 Nov; 120(11):400720.
  • 39
    Keyak JH, Koyama AK, LeBlanc A, Lu Y, Lang TF. Reduction in proximal femoral strength due to long-duration spaceflight. Bone. 2009 Mar; 44(3):44953.
  • 40
    Pedersen BK, Fischer CP. Beneficial health effects of exercise—the role of IL-6 as a myokine. Trends Pharmacol Sci. 2007 Apr; 28(4):1526.
  • 41
    Shirazi-Fard Y, Kupke JS, Bloomfield SA, Hogan HA. Discordant recovery of bone mass and mechanical properties during prolonged recovery from disuse. Bone. 2013 Jan; 52(1):43343.
  • 42
    Muir J, Judex S, Qin YX, Rubin C. Postural instability caused by extended bed rest is alleviated by brief daily exposure to low magnitude mechanical signals. Gait Posture. 2011 Mar; 33(3):42935.
  • 43
    Chan ME, Adler BJ, Green DE, Rubin CT. Bone structure and B-cell populations, crippled by obesity, are partially rescued by brief daily exposure to low-magnitude mechanical signals. FASEB J. 2012 Dec; 26(12):485563.
  • 44
    Sen B, Xie Z, Case N, Styner M, Rubin CT, Rubin J. Mechanical signal influence on mesenchymal stem cell fate is enhanced by incorporation of refractory periods into the loading regimen. J Biomech. 2011 Feb 24; 44(4):5939.
  • 45
    Colnot C, Zhang X, Knothe Tate ML. Current insights on the regenerative potential of the periosteum: molecular, cellular, and endogenous engineering approaches. J Orthop Res. 2012 Dec; 30(12):186978.
  • 46
    Evans SF, Parent JB, Lasko CE, Zhen X, Knothe UR, Lemaire T, Knothe Tate ML. Periosteum, bone's “smart” bounding membrane, exhibits direction dependent permeability. J Bone Miner Res. 2013 Mar; 28(3):60817.
  • 47
    Henrotin Y. Muscle: a source of progenitor cells for bone fracture healing. BMC Med. 2011; 9:136.
  • 48
    Tidball JG, Villalta SA. Regulatory interactions between muscle and the immune system during muscle regeneration. Am J Physiol Regul Integr Comp Physiol. 2010 May; 298(5):R1173R87.
  • 49
    Deng B, Wehling-Henricks M, Villalta SA, Wang Y, Tidball JG. IL-10 triggers changes in macrophage phenotype that promote muscle growth and regeneration. J Immunol. 2012 Oct 1; 189(7):366980.
  • 50
    Demay M. Muscle: a nontraditional 1,25-dihydroxyvitamin D target tissue exhibiting classic hormone-dependent vitamin D receptor actions. Endocrinology. 2003 Dec; 144(12):51357.
  • 51
    Bischoff-Ferrari HA, Dietrich T, Orav EJ, Hu FB, Zhang Y, Karlson EW, Dawson-Hughes B. Higher 25-hydroxyvitamin D concentrations are associated with better lower-extremity function in both active and inactive persons aged > or =60 y. Am J Clin Nutr. 2004 Sep; 80(3):7528.
  • 52
    Muir SW, Montero-Odasso M. Effect of vitamin D supplementation on muscle strength, gait and balance in older adults: a systematic review and meta-analysis. J Am Geriatr Soc. 2011 Dec; 59(12):2291300.
  • 53
    Lee SJ, McPherron AC. Myostatin and the control of skeletal muscle mass. Curr Opin Genet Dev. 1999 Oct; 9(5):6047.
  • 54
    Benny Klimek ME, Aydogdu T, Link MJ, Pons M, Koniaris LG, Zimmers TA. Acute inhibition of myostatin-family proteins preserves skeletal muscle in mouse models of cancer cachexia. Biochem Biophys Res Commun. 2010 Jan 15; 391(3):154854.
  • 55
    Villareal DT, Chode S, Parimi N, Sinacore DR, Hilton T, Armamento-Villareal R, Napoli N, Qualls C, Shah K. Weight loss, exercise, or both and physical function in obese older adults. N Engl J Med. 2011 Mar 31; 364(13):121829.
  • 56
    Shah K, Armamento-Villareal R, Parimi N, Chode S, Sinacore DR, Hilton TN, Napoli N, Qualls C, Villareal DT. Exercise training in obese older adults prevents increase in bone turnover and attenuates decrease in hip bone mineral density induced by weight loss despite decline in bone-active hormones. J Bone Miner Res. 2011 Dec; 26(12):28519.
  • 57
    Villareal DT, Kotyk JJ, Armamento-Villareal RC, Kenguva V, Seaman P, Shahar A, Wald MJ, Kleerekoper M, Fontana L. Reduced bone mineral density is not associated with significantly reduced bone quality in men and women practicing long-term calorie restriction with adequate nutrition. Aging Cell. 2011 Feb; 10(1):96102.
  • 58
    Bostrom P, Wu J, Jedrychowski MP, Korde A, Ye L, Lo JC, Rasbach KA, Bostrom EA, Choi JH, Long JZ, Kajimura S, Zingaretti MC, Vind BF, Tu H, Cinti S, Hojlund K, Gygi SP, Spiegelman BM. A PGC1-alpha-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature. 2012 Jan 26; 481(7382):4638.
  • 59
    Chien KR, Karsenty G. Longevity and lineages: toward the integrative biology of degenerative diseases in heart, muscle, and bone. Cell. 2005 Feb 25; 120(4):53344.
  • 60
    Febbraio MA. gp130 receptor ligands as potential therapeutic targets for obesity. J Clin Invest. 2007 Apr; 117(4):8419.
  • 61
    Pedersen BK, Febbraio MA. Muscles, exercise and obesity: skeletal muscle as a secretory organ. Nat Rev Endocrinol. 2012 Aug; 8(8):45765.
  • 62
    Bonewald LF. The amazing osteocyte. J Bone Miner Res. 2011 Feb; 26(2):22938.
  • 63
    Paszty C, Turner CH, Robinson MK. Sclerostin: a gem from the genome leads to bone-building antibodies. J Bone Miner Res. 2010 Sep; 25(9):189704.
  • 64
    Mo C, Romero-Suarez S, Bonewald L, Johnson M, Brotto M. Prostaglandin E2: from clinical applications to its potential role in bone-muscle crosstalk and myogenic differentiation. Recent Pat Biotechnol. 2012 Dec; 6(3):2239.
  • 65
    Jahn K, Lara-Castillo N, Brotto L, Mo CL, Johnson ML, Brotto M, Bonewald LF. Skeletal muscle secreted factors prevent glucocorticoid-induced osteocyte apoptosis through activation of beta-catenin. Eur Cell Mater. 2012; 24:197209 discussion 10.